Tedeschi A
Unità Operativa di Allergologia e Immunologia Clinica, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milano, Italy.
Eur Ann Allergy Clin Immunol. 2009 Dec;41(6):187-9.
Histamine is the main mediator of urticaria and H1-receptor antagonists represent the treatment of choice in all patients with chronic urticaria. Leukotriene receptor antagonists as montelukast have also been used in patients with chronic urticaria unresponsive to H1-antihistamines alone. We report a patient with chronic urticaria whose disease was paradoxically exacerbated by H1-antihistamines and montelukast, and controlled by immunosuppressive drugs as ciclosporin and azathioprine. Urticaria exacerbations were caused by different molecules including either piperidine (fexofenadine, desloratadine, ebastine, rupatadine) or piperazine (hydroxyzine, cetirizine) derivatives as well as by montelukast suggesting that an IgE-mediated mechanism was not involved. A possible explanation of the observed urticaria exacerbation is that H1-antihistamines and montelukast may shift the H1 histamine receptor and the leukotriene receptor to the active conformation instead of the inactive state. The beneficial effects of ciclosporin and azathioprine confirm that immunosuppressive drugs have an important role in the treatment of refractory chronic urticaria and back the hypothesis that an autoimmune/autoreactive mechanism often underlies the disease.
组胺是荨麻疹的主要介质,H1受体拮抗剂是所有慢性荨麻疹患者的首选治疗药物。白三烯受体拮抗剂如孟鲁司特也被用于单独使用H1抗组胺药无效的慢性荨麻疹患者。我们报告了一名慢性荨麻疹患者,其病情在使用H1抗组胺药和孟鲁司特后反而加重,而使用环孢素和硫唑嘌呤等免疫抑制药物后得到控制。荨麻疹加重是由不同分子引起的,包括哌啶(非索非那定、地氯雷他定、依巴斯汀、卢帕他定)或哌嗪(羟嗪、西替利嗪)衍生物以及孟鲁司特,这表明不涉及IgE介导的机制。观察到的荨麻疹加重的一个可能解释是,H1抗组胺药和孟鲁司特可能将H1组胺受体和白三烯受体转变为活性构象而非非活性状态。环孢素和硫唑嘌呤的有益作用证实,免疫抑制药物在难治性慢性荨麻疹的治疗中具有重要作用,并支持自身免疫/自身反应机制常是该疾病基础的假说。